Startup aims to give castoff Vertex drug new life as Alzheimer ’s treatment

In 2001, Vertex Pharmaceuticals announced that it was halting development of a rheumatoid arthritis drug. The treatment, which was designed to block a certain enzyme linked to inflammation, had showed promise in clinical trials, but animal studies turned up worrying side effects of the central nervous system. The drug, a small molecule with the generic name neflamapimod, was largely forgotten until a tiny Cambridge startup called EIP Pharma licensed the rights to it from Vertex in 2014. Led by a…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news